Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
NCT07495852Phase 3Recruiting
- Lead sponsor
- Glaukos Corporation (Industry)
- Enrollment
- 510 (estimated)
- Start date
- 17 Feb 2026
- Primary completion
- Jun 2028 (estimated)
- Study completion
- 1 Mar 2032
- Last update posted
- 30 Mar 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Triple
- Arms
- 6
Interventions
- Gen 2 Travoprost Intracameral Implant Drug
- Timolol eye drops 0.5% Drug
- Sham Procedure Procedure
- placebo eye drops Other
Conditions and primary outcome
- Glaucoma
Primary outcome
Intraocular pressure (IOP) (3 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07495852.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07495852 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.